Diligence memo · auto-generated · as of July 2, 2026
Sentonix, Inc.
Sentonix, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Sentonix, Inc. operates in Pharmaceuticals, based in ARLINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sentonix, Inc. has raised $6.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.5M on 2024-09-23.
Most recent recorded round closed around 2024-09-23.
Valuation (modeled)modeled
Provath models Sentonix, Inc. at approximately $30M (range $7.4M–$62M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.93× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Within the normal band (93% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 21 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 47% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 34% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.